Φορτώνει......
Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates
Human epidermal growth factor receptor 2 (HER2)-targeted therapies have revolutionized the treatment of HER2-positive breast cancer, both in the metastatic and early stage settings. While trastuzumab and lapatinib had been the mainstays of treatment in combination with chemotherapy, innate and acqui...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Ann Transl Med |
|---|---|
| Κύριοι συγγραφείς: | , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
AME Publishing Company
2014
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4260046/ https://ncbi.nlm.nih.gov/pubmed/25568875 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2305-5839.2014.08.13 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|